Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by WalkOverTheStrton Jun 08, 2020 5:45pm

160 Views

Post# 31126318

RE:6 months away from partnering (at least)

This time line estimate is based off what?
Based on past interviews with the CEO we know that Antibe was already having some discussions and those will speed up once the full data set is dropped into the data rooms.
Partnerships take time but I for one am assuming that these potential partners have digested previous Antibe studies and will add the new data to their models / valuations....

It all depends on a number of factors, one I am betting on is many BPs could easily throw $750M - $1B to buy the company if the full data sets are as promosing as the top line data AND Antibe can play more than one BP off each other.

Bullboard Posts

Calibre discovers significant gold in Newfoundland